The Microbiome Connect Europe event, by Kisaco Research, was held recently in Amsterdam, the Netherlands. The speakers covered many facets of microbiome-focused products: discovery, clinical validation and mechanisms of action, commercial development, and manufacturing. Despite several high-profile microbiome companies facing closure during the past year, the industry remains strong—the conference showcased many diverse and promising...

An in-person event, Pharmabiotics 2022, brought together individuals from academia and industry in the microbiome field to focus on how microbiome-based drug products will become a therapeutic reality in Europe. The event was hosted by PRI, an organization dedicated to navigating the regulation of microbiome medicinal products in Europe, using a collaborative approach to improve...

Companies are now targeting the gut microbiome with therapies for fatty liver disease, hepatic encephalopathy, and more.. The liver is an incredibly complex organ—and its functioning leaves very little room for error. Even minor inflammation in the liver, caused by viral disease or other factors, interferes with the liver’s crucial activities of detoxification, synthesis, and...

A virtual event held earlier this year, Microbiome Movement – Drug Development Europe 2022, provided a chance to bring together the microbiome drug development community to share updates and discuss current challenges in the field. This brief report covers some of the take-homes from the event. Interestingly, scale-up and manufacturing were identified as key challenges...

Of all the diseases and conditions linked to the gut microbiome, the inflammatory bowel diseases (IBDs) ulcerative colitis and Crohn’s disease have been some of the most promising indications for potential therapeutics. Not only did early studies show robust differences in gut bacterial communities between those with IBD and healthy controls, but also, the observed...

Lyon- France – le 20 janvier 2022 – Créée en mars 2021, APM, qui compte 22 membres, est le fruit de l’union d’acteurs publics et privés engagés dans la promotion de la science émergente du microbiote. Porte-parole et fédérateur des acteurs majeurs du développement, de la production et de la commercialisation d’innovations thérapeutiquesliées au microbiote...

Of all the respiratory diseases, one of them – COVID-19 – has been the focus of most of the research and attention over the past two years. While surely justified, this has had the effect of diverting resources away from the study of chronic respiratory diseases that urgently require solutions for clinical unmet needs: chronic...

Many colleagues in the microbiome industry were able to gather in person once again for Global Engage’s 9thMicrobiome R&D and Business Collaboration Forum: Europe. The event had a wide-ranging program covering microbiome industry updates, and was held in Rotterdam, the Netherlands, October 26-27, 2021. The presentations were a combination of live and virtual. From the...

Microbiome oncology company turns to world-leading CDMO to handle the challenges of manufacturing and scale-up Microbiome-focused oncology drug company everImmune, a spin-out from France’s top cancer research center, has signed an agreement with contract development and manufacturing organization (CDMO) Biose Industrie to manufacture the drug substance and finished drug product for its leading live biotherapeutic...

In medicine, the digestive tract (or ‘gut’) and the brain have long been treated as two separate entities – but research from the past few decades has discovered strong interconnections between the two. Recently, as scientists have advanced our understanding of the mechanisms by which the gut and the brain communicate, they have identified microorganisms...